WOODBRIDGE, ON, April 9, 2013 /CNW/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies
for cardiovascular disease (CVD) and overall health, is pleased to
announce that VASCAZEN® met its primary endpoint in the REVEAL trial. Additionally, VASCAZEN® achieved statistical significance in various secondary endpoints in
patients presenting with elevated triglycerides (>200mg/dL < 500mg/dL).
The data has been accepted for presentation at the American Heart
Association's Arteriosclerosis, Thrombosis and Vascular Biology (ATVB)
2013 Scientific Sessions (ATVB) at Lake Buena Vista, Florida, USA, May
"This data represents a significant milestone for VASCAZEN® as a treatment option for the thousands of people who are Omega-3
defeicient and suffer from elevated triglycerides yet remain below the
threshold of "very high" triglycerides required for treatment with
currently available prescription medications" said Dr. George
Jackowski, Chairman and Chief Scientific Officer. "This landmark study
is among the first that examined Omega-3 deficiency pre and post
treatment and brings the importance of its correction to the forefront
as an important part in managing CVD patients. We are very excited to
be presenting our top line results at this premier conference as it
attracts the top clinicians and scientists in all areas of
cardiovascular disease focusing on lipids and heart disease."
Dr. Jackowski gratefully acknowledges the outstanding contribution of
the Contract Research Organization (CRO), Nutrasource Diagnostics Inc.,
Guelph, Ontario, Canada, for its professional execution and management
of the VASCAZEN®-REVEAL trial. "The CRO trial team has done a superb job in the overall management of
this pivotal study," stated Dr. Jackowski.
About the Study
The VASCAZEN®-REVEAL trial is a randomized, double blind, placebo controlled, multi-center
USA based study that enrolled 110 patients. The purpose of the study
was to evaluate the effects of VASCAZEN® in the correction of Omega-3 deficiency in patients with one or more
risk factors associated with CVD, and to evaluate VASCAZEN®'s concomitant effects on cardiovascular risk factors including
triglycerides, VLDL cholesterol, LDL cholesterol, and HDL cholesterol
among others. The primary efficacy endpoint was the correction of an
Omega-3 deficiency, and secondary endpoints included positive effects
on lipid profiles, without any adverse events.
VASCAZEN® is a prescription only Medical Food specifically formulated for the
dietary management of an Omega-3 deficiency in cardiovascular patients.
VASCAZEN® is a >90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid
formulation, protected by a series of both U.S. and foreign patents. VASCAZEN® is the second to market prescription only Omega-3 therapy available in
the U.S. and is available by prescription nationwide.
About Pivotal Therapeutics Inc.
Pivotal Therapeutics is a publicly traded (OTCQX: PVTTF) (CNSX: PVO)
specialty pharmaceutical company with a focus on cardiovascular disease
and overall health. Pivotal Therapeutics' lead product VASCAZEN® is a prescription only Medical Food formulated to meet the dietary
Omega-3 deficient needs of patients with cardiovascular disease through
elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to
levels associated with reduced risk of cardiovascular complications.
The information contained in this document is as of April 9, 2013. This
press release contains forward-looking statements. Such forward-looking
statements are subject to a number of risks, assumptions and
uncertainties that could cause Pivotal's actual results to differ
materially from those projected in such forward-looking statements.
These statements can be identified by the use of words such as "will",
"anticipate", "estimate", "expect", "project", "forecast", "intend",
"plan", "believe", "project", "potential", and similar expressions with
any discussion of future operating or financial performance or events.
In particular, factors that could cause actual results to differ
materially from those in forward looking statements include the
following: Pivotal's inability to obtain additional financing on
acceptable terms; growth in costs and expenses; inability to compete
with others who provide comparable products; risk that the Company's
products will not gain widespread market acceptance; risks relating to
the Company's ability to maintain its CSNX listing. Forward-looking
statements speak only as of the date made and are not guarantees of
future performance. The Company undertakes no obligation to publicly
update or revise any forward-looking statements contained in this
document as a result of new information or future events or
developments. CNSX has not reviewed and does not accept responsibility
for the adequacy or accuracy of this information.
SOURCE: Pivotal Therapeutics Inc.
For further information:
President and Chief Operating Officer
Communications and Public Relations Manager
Phone: 905-856-9797 ext. 231